Dermatology

Filter

The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab

September 2025

Psoriatic disease extends beyond the skin, imposing a significant psychosocial burden, often leading to embarrassment, social withdrawal…

12 Sep 2025

The POSITIVE Phase IV Study: Interim 52-Week Results on Patient Well-Being With Tildrakizumab

Psoriatic disease extends beyond the skin, imposing a significant psychosocial burden, often leading to embarrassment, social withdrawal…

Development of Phage Therapies for Acne Vulgaris

Acne vulgaris, commonly known as acne, is a skin disease caused by the blockage of hair follicles, high keratin and sebum production in…

Anti-IL-23 Blocks Pathogenic T Cells

Psoriasis affects 60 million people globally. It is an inflammatory skin condition that can significantly impact quality of life…

The evolving atopic dermatitis treatment landscape

Experts provide real-life insights and case examples of managing moderate-to-severe atopic dermatitis, sharing their treatment experience with lebrikizumab.

Acne Treatment Review and Present Perspectives

Acne is a chronic inflammatory skin disease whose visible effects can have a significant psychological impact on patients. A multimodal…

Article Under Review

Nemolizumab in Atopic Dermatitis

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

30 Jan 2025

Vitiligo, Beyond White Patches

A review highlighting the need to improve vitiligo care through understanding the role of the JAK-STAT pathway, early diagnosis and…

Loading posts...

1 2 3 … 28 Next »